ARTICLE | Company News
Affimed, Merck deal
February 1, 2016 8:00 AM UTC
Affimed will fund and conduct a Phase Ib trial evaluating its AFM13 with Merck’s melanoma drug Keytruda pembrolizumab to treat relapsed or refractory Hodgkin lymphoma. The trial is expected to begin...